US pharma major AbbVie saw its shares drop 4.5% to $218.04 by close of trading on Friday, despite reporting financial results for the third quarter ended September 30, 2025, that beat expectation.
US biotech 4D Molecular Therapeutics (Nasdaq: FDMT) has granted Japan’s Otsuka Pharmaceutical (TYO: 4578) exclusive rights to ...
US anti-virals giant Gilead Sciences late yesterday announced its third quarter 2025 results of operations, reporting total ...
The top 20 global biopharmaceutical companies saw their combined market capitalization rise 4% in the third quarter of 2025 ...
King Faisal Specialist Hospital & Research Centre (KFSHRC) has begun in-house manufacturing and clinical use of CAR-T cell ...
German family-owned pharma major Boehringer Ingelheim has licensed a pre-clinical program from Japan’s Kyowa Kirin to develop ...
Merck & Co (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, while adjusted earnings rose ...
The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...
The European Medicines Agency’s Pharmacovigilance Risk Committee (PRAC) has agreed on a direct healthcare professional communication (DHPC) to remind healthcare professionals that extreme caution ...
Swiss pharma major Roche (ROG: SIX) has entered a global exclusive licensing agreement with China’s Qyuns Therapeutics for ...
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has designated Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) as interchangeable biosimilars to the ...
Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback